Cassava Sciences announces publication on basic science supporting simufilam

Cassava Sciences announced a new science publication in Drug Development Research, a peer-reviewed journal. This article reviews certain receptor-protein interactions, including an overview of basic science supporting simufilam. Simufilam is Cassava Sciences’ oral investigational drug candidate that is currently in Phase 3 clinical trials in patients with mild-to-moderate Alzheimer’s disease dementia. “This paper highlights the role of altered filamin A and its receptor interactions in Alzheimer’s disease,” said Lindsay Burns, PhD, first author and Cassava Sciences’ Senior VP, Neuroscience. “We believe the theme of receptor-protein interactions is critical to the proposed mechanism of action of simufilam, our small molecule drug candidate for patients with Alzheimer’s disease.” The review article was published on-line June 8, 2023, ahead of print and is titled “Targeting alpha7 nicotinic acetylcholine receptors and their protein interactions in Alzheimer’s disease drug development.